Patents by Inventor Lifang Lei

Lifang Lei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240325520
    Abstract: The present invention discloses a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity for various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic strains. The RBD trimer protein is taken as an antigen and supplemented with an adjuvant to immunize an organism, so that a high-titer neutralizing antibody aiming at various SARS-CoV-2 epidemic strains can be generated at the same time, and the antibody has a certain broad-spectrum property and can be used for treating and/or preventing SARS-CoV-2 infection and/or coronavirus disease 2019.
    Type: Application
    Filed: September 24, 2021
    Publication date: October 3, 2024
    Inventors: Qiming LI, Yu LIANG, Jing ZHANG, Jiguo SU, Zibo HAN, Shuai SHAO, Yanan HOU, Hao ZHANG, Shi CHEN, Yuqin JIN, Xuefeng ZHANG, Lifang DU, JunWei HOU, Zhijing MA, Zehua LEI, Fan ZHENG, Fang TANG, Zhaoming LIU, Ning LIU
  • Patent number: 8597634
    Abstract: The present invention relates to interferon (IFN)-?2a modified at a specific Lys residue with Y-shaped branched polyethylene glycol (PEG) derivative and the preparation thereof, as well as the use of the prepared IFN-?2a modified by PEG at a single amino acid residue in medicines.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: December 3, 2013
    Assignee: Biosteed Gene Expression Tech. Co., Ltd.
    Inventors: Weidong Zhou, Qingjiang Xiao, Li Sun, Tiebing Wang, Bin Liu, Song Lin, Min Liu, Fenghong Yin, Lu Zhuang, Lifang Lei
  • Publication number: 20100239532
    Abstract: The present invention relates to interferon (IFN)-?2a modified at a specific Lys residue with Y-shaped branched polyethylene glycol (PEG) derivative and the preparation thereof, as well as the use of the prepared IFN-?2a modified by PEG at a single amino acid residue in medicines.
    Type: Application
    Filed: September 4, 2007
    Publication date: September 23, 2010
    Applicant: BIOSTEED GENE EXPRESSION TECH. CO., LTD.
    Inventors: Weidong Zhou, Qingjing Xiao, Li Sun, Tlebing Wang, Bin Liu, Song Lin, Min Liu, Fenghong Yin, Lu Zhuang, Lifang Lei